CytRx announces publication of paper that independently validates its therapeutic strategy for age-progressive diseases.

CytRx, a San Diego biopharmaceutical company and a leader in molecular chaperone regulation technology, announced that a paper published in the peer-reviewed journal Gerontology concluded that molecular chaperone amplification may represent a “significant strategy” in the future design of anti-aging pharmaceuticals. The paper’s authors reviewed both clinical and animal studies, finding that molecular chaperones are important in the deterrence of protein damage during aging and found that chaperone expression is necessary for cell longevity. Jack Barber, Ph.D., Chief Scientific Officer, at CytRx commented, “The authors` conclusion of the importance of chaperones in aging coincides with our data indicating the potential of arimoclomol and iroxanadine in age-progressive indications, such as amyotrophic lateral sclerosis, also known as ALS or Lou Gehrig`s disease, as well as diabetes and its complications, cardiovascular disease, and stroke. The authors speculated that one of the ways to accomplish a pharmacologic stimulation of chaperone synthesis is to activate the transcriptional regulator Heat Shock Factor-1 (HSF-1), and that is exactly the mechanism by which arimoclomol and iroxanadine are thought to work.” CytRx expects that the FDA hold on its arimoclomol clinical trial for ALS will be lifted in the current quarter.

Click here to read more.

Share this:
Facebooktwittergoogle_plusmailFacebooktwittergoogle_plusmail